Can Extracellular Vesicles Help Diagnose Subtypes of FTD-ALS?
Ratio of 3R/4R tau in extracellular vesicles identified people with behavioral variant FTD and PSP. Vesicle TDP43 identified bvFTD and ALS.
ALL NEWS
6530 RESULTS
Sort By:
- Most Recent
- Most Commented
C1q from Microglia Meddles in Neuronal Translation
In mice, the innate immune protein slips into neurons, where it interacts with the translation machinery.
A First for Proteinopathies—Heteromeric Fibrils
In people with FTLD-TDP-43 Type C, TDP-43 and annexin A11 twist into heteromeric amyloid filaments. Could there be others?
Donanemab Approved in the U.S.
The antibody becomes the second amyloid immunotherapy to receive traditional FDA approval, joining Leqembi.
PET Tracers For Non-Alzheimer’s Tauopathies Enter Clinical Testing
New candidate OXD-2314 binds 3R and 4R forms of tau and has begun Phase 1. The pan-tau tracer APN-1607 begins Phase 3 for progressive supranuclear palsy, a 4R tauopathy.
Remember Amyloid-eta? A Decade Later, News on a Physiological Function
To modulate synapses, Aη weakens ion flux through glutamate receptors and strengthens their non-ionotropic signaling. This dual action is a first, say scientists.
T Cells in the Brain Goad Microglia to Muddle Myelin
In mouse models of amyloidosis, CD8+ T cells trigger myelin pathology by rousing microglia and confusing oligodendrocytes.
Microglial Transplants Reverse Age-Related Pathology in Mice
Mice missing microglia develop astrogliosis and neurodegeneration by middle age. Giving them healthy microglia prevents or reverses pathology.
Toward an AD CRISPR Therapy: Tweaking APP Terminus Cuts Plaque
Nixing an endosomal targeting sequence shields APP from BACE1, reducing Aβ and pathologic C-terminal fragments in mice.
All About Exposure: How to Get Enough Progranulin into the Brain?
Injected into the cerebrospinal fluid, a viral vector delivers the lysosomal protein into the human brain. In mice, a protein transport vehicle delivered into the blood does the same.
Blood May Foretell Parkinson’s Up to Seven Years Prior
A panel of eight plasma proteins identified people who were on the path to Parkinson’s. Could this help select participants for prevention trials?
Donanemab Approval Likely to Pose New Quandaries for Clinicians
With limited guidance, physicians will have to navigate questions about whom to treat, when to stop, and how to manage safety.
World Trade Center Responders at Risk for Early Onset Dementia
People who sifted through piles of debris are nine times likelier to develop early onset, all-cause dementia than those exposed to little toxic dust.
New PET Ligand Captures α-Synuclein in Parkinson’s, MSA Brains
C05-05 binds α-synuclein deposits in the mouse, marmoset, and human brain. Uptake in the PD midbrain correlated with motor symptom severity.
Unanimous: FDA Advisory Committee Backs Donanemab
All 11 committee members voted that the antibody was effective for people with MCI or mild AD dementia, with its benefits outweighing risks.
Current Filters
No filters selected